Our next guest operates a compliance strategy and services provider serving the hemp and cannabis industries nationwide. She brings a regulator’s keen eye and wide-reaching knowledge of evolving compliance and safety mandates to support businesses in tightly regulated industries.

Allay Consulting and The GMP Collective are now joining forces amid the rapid national growth of the cannabis, hemp, and emerging psychedelics sectors, with a focus on current Goods Manufacturing Practices (cGMP) compliance. 

Through this partnership, The GMP Collective will now have increased availability to focus on working with governments, standards bodies such as ASTM International, and ancillary service providers to lead the development of a cohesive regulatory framework that will align the disjointed statutes of the cannabis and hemp industries, both domestically and internationally. 

According to the Journal of the American Medical Association, there are more than 50 publicly traded companies related to the development or administration of psychedelic drugs in the U.S., with at least three valued at more than $1 billion. The U.S. market for psychedelic substances is projected to grow from $2 billion in 2020 to $10.75 billion by 2027. We talk about the appeal of psychedelics as a means of deviating and diversifying from cannabis and much more.

Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy